Scientific Due Diligence & Asset Valuation
Minimizing your investment risk. We conduct in-depth technical audits to validate the science, intellectual property, and regulatory viability of biotechnology assets before acquisition.
SERVICES (Feature List)
Technical & Scientific Evaluation:
Critical analysis of the robustness of preclinical and clinical data. Does the molecule actually work? Are the results reproducible?
Regulatory Audit:
Review of the asset's regulatory status. We identify "skeletons in the closet" (hidden compliance issues) that could block future commercialization.
Intellectual Property (IP) Review:
Preliminary analysis of Freedom-to-Operate and the strength of the patents associated with the product.
Market & Competition Valuation:
Analysis of the current and future competitive landscape to estimate the real commercial potential of the asset.
Research Team Assessment:
Evaluation of the capabilities and track record of the scientific team behind the innovation.
DIFFERENTIATION (Business Insight)
Protecting Your Capital: A great scientific idea is not always a good pharmaceutical business. At Clinical Biotec, we separate the hype from reality. Our Due Diligence report provides an objective, independent ("Clean Eyes") view, allowing you to negotiate with leverage or decide not to invest if the risk is too high. Diligence le proporciona una visión objetiva e independiente ("Ojos Limpios") para que negocie con ventaja o decida no invertir si el riesgo es demasiado alto.
Clinical Biotec S.L. – Spanish Tax ID (CIF): B56379233
Based in Madrid, Spain.
Registered in the Mercantile Registry of Madrid. We act as commercial representatives and authorized distributors for national and international companies in the technological, editorial, scientific, and academic sectors.
Email: santiago@clinicalbiotec.com
Copyright © 2023–2026 Clinical Biotec. All rights reserved.